By:
As we celebrate Mother’s Day, it’s worth recognizing that one of the most meaningful ways we can support moms isn’t just with appreciation, it’s with action. A new bipartisan effort aims to close a long-overlooked gap in healthcare, ensuring pregnant and lactating women are included in clinical research.
For too long, moms have had to make critical health decisions without clear, evidence-based guidance. In fact, while most pregnant women take medications, the majority of those drugs lack sufficient data on how they affect both mother and baby. This is not just a policy gap. It’s a real-world challenge that puts families in difficult positions during some of life’s most vulnerable moments.
The Advancing Safe Medications for Moms and Babies Act is designed to change that, modernizing research standards, improving data transparency, and ultimately giving mothers and their doctors the clarity they deserve. Because supporting moms shouldn’t stop at sentiment. It should show up in safer care, better information, and smarter policy.
The Power of Bipartisan Cooperation
The bipartisan nature of this effort isn’t just a talking point; it’s actually central to why this legislation has traction. At its core, the bill is being led by lawmakers from both parties and different regions:
- Kathy Castor (Democrat): U.S. Representative from Florida’s 14th Congressional District. First elected in 2006, she is recognized for her leadership on environmental policy, health care access, and economic development in the Tampa Bay region.
- Brian Fitzpatrick (Republican): U.S. Representative from Pennsylvania’s 1st Congressional District, serving since 2017. A former FBI Special Agent and federal prosecutor, he is recognized for his bipartisan approach and leadership on national security, public integrity, and mental health policy.
- Lauren Underwood (Democrat): American politician and registered nurse serving as the U.S. Representative for Illinois’s 14th Congressional District since 2019. She is recognized as the youngest Black woman ever elected to the U.S. Congress and a leading voice on public health and maternal care policy.
This mix matters. It signals that maternal health (and specifically the lack of research on medications for pregnant and lactating women) is being treated as a shared national problem, not a partisan issue.
What Makes This Bipartisan Effort Meaningful
1. Agreement on a real, measurable gap
All three lawmakers are aligned on a hard truth: pregnant and lactating women have historically been excluded from clinical trials, leaving doctors and patients without reliable data. This isn’t ideological, it’s a data and safety problem. That makes it easier to build consensus.
2. Focus on practical, systems-level fixes
Instead of debating broad healthcare reform, the bill targets specific, actionable changes that both parties can support:
- Updating FDA regulations to allow better inclusion in research
- Directing NIH to prioritize maternal health studies
- Increasing awareness and education for providers and patients
These are pragmatic steps that are less about politics and more about infrastructure.
3. Built on prior bipartisan groundwork
This isn’t coming out of nowhere. It builds on earlier bipartisan legislation dating back to the 2016 Safe Medications for Moms and Babies Act, which created a federal task force to identify research gaps. This shows sustained, cross-party commitment over time.
4. Backed by medical and advocacy organizations
Groups like the American College of Obstetricians and Gynecologists and March of Dimes support the effort, reinforcing that this is a policy driven by clinical need, not political positioning.
5. Lessons learned from COVID-19
One of the strongest unifying points: the pandemic exposed the consequences of excluding pregnant women from trials. It led to confusion, lower vaccination rates, and delayed guidance. That real-world failure created urgency across party lines.
The Challenge
As a mother, when I read this press release and the bill, I asked, “Wouldn’t it be difficult (if not impossible) to find expecting/lactating mothers willing to participate in clinical trials?” I mean, who would put their unborn and newborn babies at risk?
So I did some research and the short answer is: yes, it’s harder. But not for the reasons people usually assume. And “hard” doesn’t mean “not feasible.” For a long time, the default approach was to exclude pregnant and lactating women to avoid risk. That created a bigger problem: medications are still used during pregnancy, just without solid data. So moms end up making decisions in the dark, which is arguably more dangerous than carefully designed research.
Why recruitment has been challenging
- Real risk concerns: Pregnant women are understandably cautious about anything that could affect their baby.
- Ethical and legal complexity: Researchers and institutions are more risk-averse because studies involve both the mother and fetus. Liability concerns have historically discouraged inclusion.
- Logistical barriers: Pregnancy is time-sensitive, and eligibility windows for studies can be narrow. Add in work, childcare, and medical appointments, and participation becomes a heavier lift.
What’s changed
The current bipartisan effort isn’t trying to force participation, it’s trying to make participation safer, clearer, and more worthwhile.
1. Better study design
Not all trials are high-risk drug experiments. Many are:
- Observational studies: tracking outcomes of medications already being taken
- Registry-based research
- Low-risk pharmacokinetic studies: how drugs move through the body
These are far easier for participants to say yes to.
2. Stronger safeguards and transparency
Clear informed consent, continuous monitoring, and stricter oversight make it easier for women to trust the process.
3. More patient-centered incentives
Support like transportation, childcare stipends, flexible scheduling, and close medical follow-up can remove practical barriers.
4. A shift in framing: from “protection” to “inclusion”
This is the big one. The conversation is moving toward:
“You deserve evidence-based care during pregnancy, not guesswork.”
That resonates with a lot of women, especially those managing chronic conditions who need reliable data.
The Bottom Line
Ultimately, this effort reflects what thoughtful policymaking can look like when it’s grounded in real-world need and backed by bipartisan resolve. By bringing together leaders from both sides of the aisle, the legislation moves beyond rhetoric and focuses on practical solutions: modernizing research standards, increasing transparency, and directing resources toward long-overdue maternal health data.
Just as important, it reframes how we approach clinical research for pregnant and lactating women. Rather than excluding them in the name of protection, it prioritizes safer, more responsible inclusion. We can better support them through low-risk study designs, stronger oversight, and clearer informed consent. The reality is these medications are already being used; this approach simply ensures they are studied with intention instead of uncertainty.
In that sense, the bill does more than close a research gap, it builds trust. Trust that moms won’t be left to make critical health decisions without evidence. And trust that when both parties align around a shared, human-centered problem, meaningful progress is achievable.
Join the Conversation
MASA is building a community committed to thoughtful dialogue, shared solutions, and a more sensible civic future. If this message resonates, we invite you to engage, contribute, and help repattern how democracy shows up in everyday life.
Follow MASA on LinkedIn and Bluesky for more stories, insights, and opportunities to get involved in building a more united and forward-thinking America.